يعرض 1 - 10 نتائج من 26 نتيجة بحث عن '"Paydas, Semra"', وقت الاستعلام: 1.40s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Marmara Üniversitesi , Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü, 3423848

    العلاقة: JOURNAL OF CHEMOTHERAPY; BAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., Tataroglu ozyukseler D., Ayhan M., Sendur M. A. , Dogan M., et al., "Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study", JOURNAL OF CHEMOTHERAPY, 2022; vv_1032021; av_07be9860-a99f-4369-b0c2-4274fbb4a5c7; http://hdl.handle.net/20.500.12627/181496Test; https://doi.org/10.1080/1120009x.2022.2073159Test; https://avesis.istanbul.edu.tr/api/publication/07be9860-a99f-4369-b0c2-4274fbb4a5c7/fileTest

  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية

    المساهمون: İstanbul Üniversitesi ,, 2636235

    العلاقة: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY; Tural D., Olmez O. F. , Sumbul A. T. , Ozhan N., ÇAKAR B., Kostek O., Ekenel M., ERMAN M., COŞKUN H. Ş. , Selcukbiricik F., et al., "Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab", INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.26, ss.1506-1513, 2021; av_8d62a86a-0e4f-4339-9426-b0070cd55957; vv_1032021; http://hdl.handle.net/20.500.12627/172390Test; https://doi.org/10.1007/s10147-021-01936-6Test; 26; 1506; 1513

  4. 4
    دورية أكاديمية

    المساهمون: Necmeddin Erbakan Univ ,, 2513623

    العلاقة: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY; Bilgin B., Sendur M. A. N. , Yucel S., Celik E., Ozyukseler D. T. , Ayhan M., BAŞOĞLU TÜYLÜ T., Ilhan A., Akdeniz N., Gulmez A., et al., "Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021; vv_1032021; av_b69c7d9b-0c65-486a-bb32-b6c885e97255; http://hdl.handle.net/20.500.12627/1636Test; https://doi.org/10.1007/s00432-020-03501-6Test

  5. 5
    دورية أكاديمية

    المساهمون: Dr. Ersin Arslan Education & Research Hospital ,, 2646052

    العلاقة: CANCER INVESTIGATION; Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M. , SEYDAOĞLU G., BİLİCİ M., ŞİMŞEK M., TEKİN S. B. , Calikusu Z., et al., "Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience", CANCER INVESTIGATION, 2021; av_aac8c4f6-ce5e-44fd-87c4-875edd940669; vv_1032021; http://hdl.handle.net/20.500.12627/173315Test; https://doi.org/10.1080/07357907.2021.1933011Test

  6. 6
    دورية أكاديمية

    المساهمون: Ankara City Hosp ,, 2703289

    العلاقة: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY; Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., Ak N., Yucel S., Ayhan M., EROL C., et al., "The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021; vv_1032021; av_ffd69354-68f8-4566-8d23-aeea4c28d53f; http://hdl.handle.net/20.500.12627/175958Test; https://doi.org/10.1007/s00432-021-03748-7Test

  7. 7
    دورية أكاديمية

    المساهمون: Rabin Medical Center ,, 2288122

    العلاقة: LUNG CANCER; Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B. , et al., "GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients", LUNG CANCER, cilt.148, ss.48-54, 2020; vv_1032021; av_1467efc6-fcdf-43c6-a061-5b18428ff9fd; http://hdl.handle.net/20.500.12627/19120Test; https://doi.org/10.1016/j.lungcan.2020.07.022Test; 148; 48; 54

  8. 8
    دورية أكاديمية

    المساهمون: Acibadem Hospitals Group ,, 2285836

    العلاقة: EUROPEAN JOURNAL OF CANCER CARE; Alkan A., Yasar A., Guc Z. G. , Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., Basal F. B. , TÜRK H. M. , Ozdemir O., Cinkir H. Y. , et al., "Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)", EUROPEAN JOURNAL OF CANCER CARE, 2020; vv_1032021; av_336ebf03-e868-4963-8d5d-7d58a87c584c; http://hdl.handle.net/20.500.12627/3936Test; https://doi.org/10.1111/ecc.13296Test

  9. 9
    دورية أكاديمية

    المساهمون: İstanbul Teknik Üniversitesi ,, 2277565

    العلاقة: ANNALS OF HEMATOLOGY; Ozbalak M., SALİHOĞLU A., Soysal T., Karadogan I., PAYDAŞ S., Ozdemir E., Yildiz B., Karadurmus N., KAYNAR L., Yagci M., et al., "Long-term results of brentuximab vedotin in relapsed and refractory Hodgkin lymphoma: multi-center real-life experience", ANNALS OF HEMATOLOGY, cilt.99, ss.301-307, 2020; vv_1032021; av_f3632a2f-42dd-4a8f-87d2-6b8e4db55413; http://hdl.handle.net/20.500.12627/159618Test; https://doi.org/10.1007/s00277-019-03899-1Test; 99; 301; 307

  10. 10
    دورية أكاديمية

    المساهمون: İstanbul Medipol Üniversitesi ,, 2637711

    العلاقة: ANNALS OF HEMATOLOGY; Bekoz H., ÖZBALAK M. M. , Karadurmus N., PAYDAŞ S., Turker A., TOPTAŞ T., Tuglular T. F. , Altuntas F., Cakar M. K. , SÖNMEZ M., et al., "Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience", ANNALS OF HEMATOLOGY, cilt.99, sa.11, ss.2565-2576, 2020; vv_1032021; av_c4868fa1-b94a-4f2a-9d8c-9d6be787421c; http://hdl.handle.net/20.500.12627/174120Test; https://doi.org/10.1007/s00277-020-04077-4Test; 99; 11; 2565; 2576